ZertifikateAwards 2021/2022: Bitte stimmen Sie für finanzen.net zero und finanzen.net ab und gewinnen Sie eine Reise nach Berlin! -w-

Sanofi Aktie

82,67EUR
+0,02EUR
+0,02%
19.10.2021
82,58EUR
-0,17EUR
-0,21%
19.10.2021

WKN: 920657 / ISIN: FR0000120578

  Kaufen  
Verkaufen
oder
Werbung

Sanofi Aktien News

13.10.21
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021  (EN, Sanofi-Aventis)
13.10.21New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021  (GlobeNewswire)
12.10.21
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022 (EN, Sanofi-Aventis)
07.10.21
Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations (EN, Sanofi-Aventis)
30.09.21
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (EN, Sanofi-Aventis)
30.09.21New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (GlobeNewswire)
28.09.21
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate (EN, Sanofi-Aventis)
28.09.21
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (EN, Sanofi-Aventis)
28.09.21Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (GlobeNewswire)
27.09.21
New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection (EN, Sanofi-Aventis)
24.09.21Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (GlobeNewswire)
24.09.21
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (EN, Sanofi-Aventis)
22.09.21KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN (PR Newswire)
21.09.21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (EN, Sanofi-Aventis)
21.09.21New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (GlobeNewswire)
19.09.21
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC (EN, Sanofi-Aventis)
19.09.21ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC (GlobeNewswire)
14.09.21Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (GlobeNewswire)
14.09.21
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (EN, Sanofi-Aventis)
10.09.21SHAREHOLDER ALERT: WeissLaw LLP Investigates Kadmon Holdings, Inc. (PR Newswire)
09.09.21ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc. (PR Newswire)
09.09.21
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus (EN, Sanofi-Aventis)
09.09.21Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus (GlobeNewswire)
08.09.21
Sanofi to acquire Kadmon to further strengthen growth of transplant business (EN, Sanofi-Aventis)
08.09.21Sanofi to acquire Kadmon to further strengthen growth of transplant business (GlobeNewswire)
03.09.21
Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress (EN, Sanofi-Aventis)
30.08.21Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in chi (GlobeNewswire)
06.08.21FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease (GlobeNewswire)
06.08.21
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease (EN, Sanofi-Aventis)
05.08.21Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer (GlobeNewswire)
05.08.21
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer (EN, Sanofi-Aventis)
03.08.21SHAREHOLDER ALERT: WeissLaw LLP Investigates Translate Bio, Inc. (PR Newswire)
03.08.21
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development (EN, Sanofi-Aventis)
03.08.21Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development (GlobeNewswire)
29.07.21Online availability of Sanofi’s half-year financial report for 2021 (GlobeNewswire)
29.07.21
Online availability of Sanofi’s half-year financial report for 2021 (EN, Sanofi-Aventis)
29.07.21
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI (EN, Sanofi-Aventis)
29.07.21Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI (GlobeNewswire)
29.07.21
Sales growth accelerated - Full-year guidance raised (EN, Sanofi-Aventis)
29.07.21
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients   (EN, Sanofi-Aventis)
Seite: 123456789...12

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln